Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Journey Medical (DERM) Research & Development (2021 - 2025)

Journey Medical (DERM) has disclosed Research & Development for 5 consecutive years, with $287000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Research & Development fell 65.91% year-over-year to $287000.0, compared with a TTM value of $544000.0 through Sep 2025, down 95.12%, and an annual FY2024 reading of $9.9 million, up 30.71% over the prior year.
  • Research & Development was $287000.0 for Q3 2025 at Journey Medical, up from $39000.0 in the prior quarter.
  • Across five years, Research & Development topped out at $7.9 million in Q1 2024 and bottomed at $39000.0 in Q1 2025.
  • Average Research & Development over 5 years is $2.0 million, with a median of $1.6 million recorded in 2023.
  • The sharpest move saw Research & Development soared 291.64% in 2022, then crashed 99.51% in 2025.
  • Year by year, Research & Development stood at $2.0 million in 2021, then soared by 113.65% to $4.3 million in 2022, then crashed by 64.64% to $1.5 million in 2023, then plummeted by 85.51% to $218000.0 in 2024, then skyrocketed by 31.65% to $287000.0 in 2025.
  • Business Quant data shows Research & Development for DERM at $287000.0 in Q3 2025, $39000.0 in Q1 2025, and $218000.0 in Q4 2024.